$2.17
-0.03[-1.36%]
At close: Apr 26
$2.17
0[0.00%]
After Hours: 4:20PM EDT
Lyell Immunopharma
(NASDAQ:LYEL)Lyell Immunopharma Stock (NASDAQ:LYEL), Analyst Ratings, Price Targets, Predictions
Lyell Immunopharma Inc has a consensus price target of $10.33, established from looking at the 16 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., HC Wainwright & Co., and JP Morgan on February 29, 2024, November 9, 2023, and August 28, 2023. With an average price target of $6.33 between HC Wainwright & Co., HC Wainwright & Co., and JP Morgan, there's an implied 191.86% upside for Lyell Immunopharma Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
JP Morgan
Morgan Stanley
Goldman Sachs
B of A Securities
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Lyell Immunopharma
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 02/29/2024 | LYEL | Buy Now | Lyell Immunopharma | $2.17 | 176.5% | HC Wainwright & Co. | Mitchell Kapoor | $8 → $6 | Maintains | Buy | Get Alert |
| 11/09/2023 | LYEL | Buy Now | Lyell Immunopharma | $2.17 | 268.66% | HC Wainwright & Co. | Mitchell Kapoor | $9 → $8 | Maintains | Buy | Get Alert |
| 08/28/2023 | LYEL | Buy Now | Lyell Immunopharma | $2.17 | 130.41% | JP Morgan | Eric Joseph | $15 → $5 | Downgrade | Overweight → Neutral | Get Alert |
| 05/05/2023 | LYEL | Buy Now | Lyell Immunopharma | $2.17 | 314.75% | HC Wainwright & Co. | Mitchell Kapoor | → $9 | Reiterates | → Buy | Get Alert |
| 03/02/2023 | LYEL | Buy Now | Lyell Immunopharma | $2.17 | 314.75% | HC Wainwright & Co. | Mitchell Kapoor | $11 → $9 | Maintains | Buy | Get Alert |
| 01/24/2023 | LYEL | Buy Now | Lyell Immunopharma | $2.17 | 84.33% | Morgan Stanley | Matthew Harrison | $7 → $4 | Maintains | Equal-Weight | Get Alert |
| 11/14/2022 | LYEL | Buy Now | Lyell Immunopharma | $2.17 | 222.58% | Morgan Stanley | Matthew Harrison | $15 → $7 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 11/11/2022 | LYEL | Buy Now | Lyell Immunopharma | $2.17 | — | Goldman Sachs | Salveen Richter | — | Downgrade | Buy → Neutral | Get Alert |
| 10/17/2022 | LYEL | Buy Now | Lyell Immunopharma | $2.17 | 453% | HC Wainwright & Co. | Mitchell Kapoor | → $12 | Initiates | → Buy | Get Alert |
| 05/24/2022 | LYEL | Buy Now | Lyell Immunopharma | $2.17 | 453% | Goldman Sachs | Salveen Richter | $21 → $12 | Maintains | Buy | Get Alert |
| 03/31/2022 | LYEL | Buy Now | Lyell Immunopharma | $2.17 | 867.74% | Goldman Sachs | Salveen Richter | $31 → $21 | Maintains | Buy | Get Alert |
| 01/06/2022 | LYEL | Buy Now | Lyell Immunopharma | $2.17 | 821.66% | Morgan Stanley | Matthew Harrison | $25 → $20 | Maintains | Overweight | Get Alert |
| 07/12/2021 | LYEL | Buy Now | Lyell Immunopharma | $2.17 | 1052.07% | Morgan Stanley | Matthew Harrison | — | Initiates | → Overweight | Get Alert |
| 07/12/2021 | LYEL | Buy Now | Lyell Immunopharma | $2.17 | 1052.07% | B of A Securities | Geoff Meacham | — | Initiates | → Buy | Get Alert |
| 07/12/2021 | LYEL | Buy Now | Lyell Immunopharma | $2.17 | 913.82% | JP Morgan | — | — | Initiates | → Overweight | Get Alert |
| 07/12/2021 | LYEL | Buy Now | Lyell Immunopharma | $2.17 | 1282.49% | Goldman Sachs | Salveen Richter | — | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Lyell Immunopharma (LYEL)?
The latest price target for Lyell Immunopharma (NASDAQ: LYEL) was reported by HC Wainwright & Co. on February 29, 2024. The analyst firm set a price target for $6.00 expecting LYEL to rise to within 12 months (a possible 176.50% upside). 4 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Lyell Immunopharma (LYEL)?
The latest analyst rating for Lyell Immunopharma (NASDAQ: LYEL) was provided by HC Wainwright & Co., and Lyell Immunopharma maintained their buy rating.
When was the last upgrade for Lyell Immunopharma (LYEL)?
There is no last upgrade for Lyell Immunopharma.
When was the last downgrade for Lyell Immunopharma (LYEL)?
The last downgrade for Lyell Immunopharma Inc happened on August 28, 2023 when JP Morgan changed their price target from $15 to $5 for Lyell Immunopharma Inc.
When is the next analyst rating going to be posted or updated for Lyell Immunopharma (LYEL)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Lyell Immunopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Lyell Immunopharma was filed on February 29, 2024 so you should expect the next rating to be made available sometime around February 28, 2025.
Is the Analyst Rating Lyell Immunopharma (LYEL) correct?
While ratings are subjective and will change, the latest Lyell Immunopharma (LYEL) rating was a maintained with a price target of $8.00 to $6.00. The current price Lyell Immunopharma (LYEL) is trading at is $2.17, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.